Over the past two decades, Dr. Douglas G. McNeel from the Department of Medicine at the University of Wisconsin has been making sustained effort in studying prostate cancer immunology with an aim to develop effective anti-tumor vaccines to treat prostate cancer. His team has specifically focused on DNA vaccines as T cell activating therapies with research aiming to understand their mechanisms of action and resistance. Chinese Clinical Oncology (CCO) is honored to interview Dr. McNeel, who will share with us what he regards as the critical issues facing the field of prostate cancer immunology, the significance of his proposed rodent model in the evaluation of immunological treatments, the current funded research project that he is involved in, and his candid advice to young researchers in developing their career.
